Will Production Bottlenecks For BMS’s Abecma Pose Problems After EU Approval?
Abecma has won conditional approval in the EU for certain multiple myeloma patients
BMS’s pioneering BCMA-directed CAR T-cell immunotherapy has been conditionally approved in the EU to treat certain patients with multiple myeloma, five months after getting the greenlight in the US where high demand for the drug has met production constraints.
